Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the transaction, the director now owns 137,155 shares in the company, valued at $2,741,728.45. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $1.14 during mid-day trading on Monday, hitting $19.94. The company’s stock had a trading volume of 745,161 shares, compared to its average volume of 218,023. The business’s fifty day moving average is $16.77 and its two-hundred day moving average is $14.21. The stock has a market cap of $821.53 million, a price-to-earnings ratio of -9.03 and a beta of 1.06. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. Tower Research Capital LLC TRC purchased a new position in Enliven Therapeutics during the first quarter worth approximately $36,000. Ameritas Investment Partners Inc. purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth $39,000. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the 4th quarter valued at approximately $28,000. Royal Bank of Canada boosted its holdings in Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock valued at $63,000 after purchasing an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Enliven Therapeutics in the fourth quarter valued at $66,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

Separately, Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.